Clinical Trials · NCT00866658

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Name: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lixisenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 311
Start date: Mar 2009
Locations: 4 sites, 4 countries
Primary endpoint: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

View Lixisenatide compound reference